First Trust Advisors LP Cerevel Therapeutics Holdings, Inc. Transaction History

First Trust Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$25.35 - $31.96 $814,267 - $1.03 Million	-32,121 Reduced 54.5%	26,813 $845,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $565,462 - $918,488	22,175 Added 60.33%	58,934 $1.67 Million
Q2 2022 Aug 12, 2022	SELL	$20.62 - $37.15 $1.2 Million - $2.15 Million	-57,993 Reduced 61.21%	36,759 $972,000
Q1 2022 May 13, 2022	SELL	$23.5 - $35.38 $288,439 - $434,254	-12,274 Reduced 11.47%	94,752 $3.32 Million
Q4 2021 Feb 08, 2022	BUY	$29.21 - $44.64 $1.61 Million - $2.46 Million	55,029 Added 105.83%	107,026 $3.47 Million
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $1.11 Million - $2.02 Million	51,997 New	51,997 $1.53 Million

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.